Century Therapeutics develops allogeneic, induced pluripotent stem cell (iPSC)-derived NK and T cell therapies to treat hematological and solid tumor malignancies, as well as autoimmune diseases. Their platform addresses the limitations of existing cell therapies by providing scalable, fit-for-purpose products with enhanced functionalities.
Funding
$60M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BCFounders
Product
Problem
Existing cell therapies for cancer and autoimmune diseases face limitations in scalability and functionality. Current approaches struggle to produce consistent, fit-for-purpose cell therapies in sufficient quantities to meet patient needs.
Solution
Century Therapeutics develops allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) to address the limitations of existing cell therapies. Their platform leverages the self-renewing capacity of iPSCs alongside cellular engineering and manufacturing technologies to create scalable, fit-for-purpose products. These therapies are designed with enhanced functionalities to improve treatment outcomes for hematological and solid tumor malignancies, as well as autoimmune diseases.
Target Audience
The primary target audience includes patients with hematological malignancies, solid tumors, and autoimmune diseases, as well as healthcare providers seeking advanced cell therapy options.
Features
- Allogeneic cell therapies derived from iPSCs
- Scalable manufacturing process for consistent product supply
- Cellular engineering for enhanced therapeutic functionalities
- Development of NK and T cell therapies
- Targeting hematological and solid tumor malignancies
- Targeting autoimmune diseases